Showing results (191-200 of 277) with videos related to
Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalPeter C Fong, Timothy A Yap, David S Boss, et al.Radiology|August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activityChristina Messiou, Matthew Orton, Joo Ern Ang, et al.Blood|October 20, 2011
Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemiaAndrea Kühnl, Nicola Gökbuget, Martin Kaiser, et al.Leukemia Research|September 9, 2011
High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemiaAndrea Kühnl, Martin Kaiser, Martin Neumann, et al.European Journal of Haematology|December 24, 2009
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myelomaMartin Kaiser, Britta Lamottke, Maren Mieth, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 31, 2024
An Attribution of Value Framework for Combination TreatmentsAndrew H Briggs, Alexis Doyle-Connolly, John Schneider, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin F Kaiser, Andrew Hall, Katrina Walker, et al.Research Square|March 30, 2023
Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controlsMolly Went, Amit Sud, Charlie Mills, et al.European Journal of Haematology|November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphomaUlrike Heider, Ivana von Metzler, Martin Kaiser, et al.American Journal of Hematology|September 10, 2025
European Myeloma Network Consensus Statement on Functional High-Risk Multiple MyelomaSueh-Li Lim, Monika Engelhardt, Evangelos Terpos, et al.Pageof 28